Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study

“…Similar results have been found for second-line platinum-based therapy, with a higher likelihood of response associated with a longer platinum-free interval. [18] We also confirmed that responses are observed in all histologic subtypes of endometrial cancer. The responses seen in two of four women with clear cell carcinoma are very encouraging for benefit in women with that rare histology.…”

Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma

“…In the Japanese retrospective study of second-line platinum therapy in endometrial cancer, response rates of 61% to 64% were seen for patients with platinum-free interval of more than 12 months and 38% with platinum-free interval of 6 to 12 months. 30 In conclusion, the current study demonstrates that the combination of bevacizumab, paclitaxel, and carboplatin is active and tolerable in a larger cohort of patients with advanced and recurrent endometrial carcinoma.…”

Outcome of Recurrent Uterine Papillary Serous Carcinoma Treated With Platinum-Based Chemotherapy

“…Recently, a multi-institutional Japanese study investigated the applicability of the concept of ''platinum sensitivity'' in 262 patients with recurrent endometrial cancer who received prior platinum-based CT. The authors included all histology types and reported significant correlation between platinum-free interval and response and survival after second-line platinum-based CT. 8 The response rate was 25% for those with platinum-free interval of less than 6 months compared with 38% to 65% in those with platinum-free interval of 6 months or longer. Furthermore, another small Japanese study investigated the outcome of second-line platinum-based CT in those with recurrent endometrial cancer who received prior platinum and taxane CT. Platinum-free interval of greater than 6 months was a significant predictor of response to CT, PFS, and OS.…”

“…Furthermore, it is unknown whether the concepts of ''platinum-free interval'' and ''platinum resistance'' as they are understood in ovarian cancer apply to patients with UPSC. Recently, a Japanese retrospective study confirmed the impact of platinum-free interval on response and outcome after second platinum-based CT. 8 McMeekin et al, 9 using ancillary data from the Gynecologic Oncology Group, found no difference in response to various chemotherapeutic agents between endometrioid, serous, and clear cell histology in patients with advanced or recurrent endometrial cancers. However, this study included only patients who did not receive prior CT and did not look at the impact of prior platinum therapy and platinum-free interval.…”